| アブストラクト | BACKGROUND: Pertussis is an endemic respiratory tract infection caused by Bordetella pertussis that may affect all individuals from infants to older adults. Pertussis incidence in adults is often underreported and in various countries, including the United Kingdom (UK), there are evidence gaps on pertussis-associated economic burden in the older adult population. We aimed to quantify the economic burden of pertussis in adults aged >/=50 years in the UK. METHODS: A cost-of-illness study was conducted to estimate the cost of pertussis from a societal perspective. We utilized a sum diagnosis cost approach in which costs related to infection with pertussis were included. Medical, patient, and indirect costs were calculated individually and combined to calculate total costs. A framework was developed to assess costs for consecutive age groups from 50-54 years of age to >/=85 years of age. Sensitivity and scenario analyses were used to assess analysis uncertainty. RESULTS: The base-case analysis estimated the total annual economic burden of pertussis to be approximately pound238 million (M). This comprised approximately pound159 M in indirect costs, pound66 M in medical costs, and pound13 M in patient costs. Costs for the age group 55-59 years had the highest impact on the economic burden, with approximately pound79 M in total annual costs. Visits to general practitioners and nurses were the largest contributors to medical costs ( approximately pound37 M) followed by inpatient visits ( approximately pound21 M). Transportation costs ( approximately pound10 M) were the major patient costs. Productivity loss ( approximately pound71 M) and leisure time loss ( approximately pound72 M) had comparable contributions to annual indirect costs. Sensitivity and scenario analyses suggested that incidence rates, indirect costs, and underreporting estimates had the highest impact on outcomes. CONCLUSION: Total cost of pertussis in the UK among adults >/=50 years of age is substantial and highest for adults 55-59 years of age. Indirect costs were the main contributors to the economic burden. |
|---|
| ジャーナル名 | Vaccine |
|---|
| Pubmed追加日 | 2023/10/16 |
|---|
| 投稿者 | Versteeg, Jan-Willem; Jamet, Nicolas; Redekop, Ken |
|---|
| 組織名 | Erasmus School of Health Policy & Management, Rotterdam, the Netherlands.;GSK, Wavre, Belgium. Electronic address: nicolas.x.jamet@gsk.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37839946/ |
|---|
